Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial

Gravestock, Paul, Clark, Emma, Morton, Miranda, Sharma, Shirya, Fisher, Holly, Walker, Jenn, Wood, Ruth, Hancock, Helen, Waugh, Nichola, Cooper, Aislinn, Maier, Rebecca, Marshall, John, Chandler, Robert, Bahl, Amit, Crabb, Simon, Jain, Suneil, Pedley, Ian, Jones, Rob, Staffurth, John ORCID: https://orcid.org/0000-0002-7834-3172 and Heer, Rakesh 2023. Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. NIHR Open Research 2 , 49. 10.3310/nihropenres.13284.2

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Background: Prostate cancer is the most commonly diagnosed malignancy in the UK. Castrate resistant prostate cancer (CRPC) can be difficult to manage with response to next generation hormonal treatment variable. AR-V7 is a protein biomarker that can be used to predict response to treatment and potentially better inform management in these patients. Our aim was to establish the feasibility of conducting a definitive randomised controlled trial comparing the clinical utility of AR-V7 biomarker assay in personalising treatments for patients with metastatic CRPC within the United Kingdom (UK) National Health Service (NHS). Due to a number of issues the trial was not completed successfully, we aim to discuss and share lessons learned herein. Methods: We conducted a randomised, open, feasibility trial, which aimed to recruit 70 adult men with metastatic CRPC within three secondary care NHS trusts in the UK to be run over an 18-month period. Participants were randomised to personalised treatment based on AR-V7 status (intervention) or standard care (control). The primary outcome was feasibility, which included: recruitment rate, retention and compliance. Additionally, a baseline prevalence of AR-V7 expression was to be estimated. Results: Fourteen participants were screened and 12 randomised with six into each arm over a nine-month period. Reliability issues with the AR-V7 assay meant prevalence was not estimated. Due to limited recruitment the study did not complete to target. Conclusions: Whilst the trial did not complete to target, we have ascertained that men with advanced cancer are willing to take part in trials utilising biomarker guided treatment. A number of issues were identified that serve as important learning points in future clinical trials.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Publisher:	Taylor and Francis
ISSN:	2633-4402
Date of First Compliant Deposit:	15 May 2023
Date of Acceptance:	10 January 2023
Last Modified:	18 May 2023 19:20
URI:	https://orca.cardiff.ac.uk/id/eprint/159495

Actions (repository staff only)

Edit Item